DFFN | Diffusion Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.17 - 5.19
52 Week Range	4.14 - 14.37
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	349,445
Average Volume	47,812
Shares Outstanding	2,040,289
Market Cap	8,977,272
Sector	Healthcare
Industry	Biotechnology
IPO Date	2008-05-23

Valuation
Profitability
Growth
Health
P/E Ratio	-0.62
Forward P/E Ratio	N/A
EPS	-7.11
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

DFFN's peers: ACST, ADIL, AEZS, AIM, AKTX, BNTC, BPTH, BRTX, CAPR, CLRB, IBIO, ITRM, JAGX, MBRX, PTN, PULM, SEEL, SLNO, TNXP, IMNN, TOVX

*Chart delayed

Analyzing fundamentals for DFFN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see DFFN Fundamentals page.

Watching at DFFN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DFFN Technicals page.